Nurix Therapeutics Stock Filter Stocks by Fundamentals
| NRIX Stock | USD 11.21 0.88 7.28% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Nurix Therapeutics' long-term financial health and intrinsic value.
Nurix | Shares Owned by Institutions | Build AI portfolio with Nurix Stock |
Nurix Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nurix Therapeutics from analyzing Nurix Therapeutics' financial statements. These drivers represent accounts that assess Nurix Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nurix Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.2B | 602.3M | 338.0M | 1.5B | 1.3B | 1.4B | |
| Enterprise Value | 1.2B | 549.7M | 314.0M | 1.4B | 1.3B | 1.3B |
Nurix Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nurix Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nurix Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Nurix Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Nurix Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nurix Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nurix Therapeutics' value.| Shares | Soleus Capital Management, L.p. | 2025-03-31 | 2.4 M | Pictet Asset Manangement Sa | 2025-03-31 | 1.8 M | Geode Capital Management, Llc | 2025-03-31 | 1.7 M | Ark Investment Management Llc | 2025-03-31 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.5 M | Ra Capital Management, Llc | 2025-03-31 | 1.3 M | Citadel Advisors Llc | 2025-03-31 | 1.3 M | Vestal Point Capital Lp | 2025-03-31 | 1.1 M | Millennium Management Llc | 2025-03-31 | 874.4 K | Fmr Inc | 2025-03-31 | 10.3 M | Blackrock Inc | 2025-03-31 | 8 M |
Nurix Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (3.41) % | ||||
| Current Valuation | 536.29 M | ||||
| Shares Outstanding | 76.45 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 14.07 M | ||||
| Price To Book | 2.08 X | ||||
| Price To Sales | 16.38 X | ||||
| Revenue | 54.55 M | ||||
| Gross Profit | (184.87 M) | ||||
| EBITDA | (196.6 M) | ||||
| Net Income | (193.57 M) | ||||
| Cash And Equivalents | 344.48 M | ||||
| Cash Per Share | 7.31 X | ||||
| Total Debt | 28.3 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.26 X | ||||
| Book Value Per Share | 5.86 X | ||||
| Cash Flow From Operations | (172.58 M) | ||||
| Short Ratio | 17.31 X | ||||
| Earnings Per Share | (2.60) X | ||||
| Target Price | 30.33 | ||||
| Number Of Employees | 286 | ||||
| Beta | 2.16 | ||||
| Market Capitalization | 924.27 M | ||||
| Total Asset | 669.34 M | ||||
| Retained Earnings | (738.77 M) | ||||
| Working Capital | 523.53 M | ||||
| Net Asset | 669.34 M |
About Nurix Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nurix Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.